Bolt Biotherapeutics acquires Prana Therapies in $120m PIPE deal
Bolt Biotherapeutics has completed the acquisition of clinical-stage biotech Prana Therapies and simultaneously closed a $120 million private placement, pivoting its strategic focus toward a pipeline of half-life-extended multispecific antibodies for inflammatory disease. The Nasdaq-listed company said the combined transactions are expected to fund operations into 2028 and through multiple anticipated clinical milestones.
The deal was structured as a sign-and-close reverse merger, with Prana shareholders receiving a combination of Bolt common stock and Series D non-voting convertible preferred stock. On a fully diluted, as-converted basis, pre-acquisition Bolt stockholders will hold approximately 6.9% of the combined company, Prana equityholders approximately 51.7%, and private placement investors approximately 41.4%, reflecting the scale of the strategic reorientation.
The asset: PRA-216 and the INSPIRE platform
The centrepiece of the acquisition is PRA-216, a fully human, half-life-extended bispecific antibody that simultaneously targets IL-4Rα and TSLP, two nodes in the Type 2 inflammatory cascade. By blocking IL-4Rα, PRA-216 suppresses downstream IL-4 and IL-13 signalling; by inhibiting TSLP upstream, it addresses an additional driver of eosinophilic and allergic inflammation. Phase 2 studies in asthma, COPD and atopic dermatitis are already under way, with a fourth Phase 2 in eosinophilic oesophagitis planned. Patient data from all four trials are expected beginning in the second quarter of 2027.
Phase 1 data from a healthy volunteer study, presented as a late-breaking abstract at the 2026 European Respiratory Society meeting, showed PRA-216 was well tolerated and produced rapid, deep, and durable pharmacodynamic effects across multiple Type 2 biomarkers, including pSTAT6, serum TARC, blood eosinophils and IgE. The compound also demonstrated bioavailability consistent with subcutaneous at-home maintenance dosing every eight to twelve weeks, a profile the company says could differentiate it from existing standard-of-care biologics that typically require more frequent clinic visits.
Underlying the drug is Prana's proprietary INSPIRE platform, which the company says is engineered to address common failure modes in multispecific antibody development: short half-life, poor stability, manufacturing complexity, immunogenicity risk and limited subcutaneous bioavailability. A second programme, an IL-31 bispecific initially targeting atopic dermatitis, is expected to enter first-in-human studies in the second half of 2027, with two further undisclosed programmes advancing toward IND-enabling work over the same period.
Market context and competitive landscape
The Type 2 inflammatory biologics market is both large and intensely contested. Dupilumab, Sanofi and Regeneron's IL-4Rα blocker, generated revenues well in excess of $10 billion annually before facing biosimilar pressure, while Amgen and AstraZeneca's TSLP inhibitor tezepelumab has established a foothold in severe asthma. A bispecific that targets both pathways simultaneously and can be dosed every two to three months would, if the clinical profile holds in Phase 2, carry a compelling commercial proposition in asthma and atopic dermatitis.
The private placement attracted a prominent syndicate that includes Andreessen Horowitz (a16z), Deep Track Capital and Casdin Capital, among others, underscoring sustained venture and crossover interest in best-in-class inflammatory biology despite a broader cooling in biotech financing conditions. An additional $60 million is available through accompanying warrants, the exercise of which is tied to disclosure of Phase 1 data from the IL-31 bispecific programme.
Sheila Gujrathi, Prana's co-founder and former chief executive, has joined Bolt's executive team as Chief Strategy Officer and taken a seat on the board, providing continuity of scientific and operational leadership through the forthcoming Phase 2 readout cycle. The critical near-term test will be whether PRA-216's Phase 1 pharmacodynamic signal translates into clinical efficacy in the patient populations now being enrolled.